Sanofi (France) Pulls the Plug on Two Late-Stage Drugs, Plans $285 Million Charge
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sanofi (SAN)’s experimental cancer treatment iniparib failed to help lung-cancer patients in a late-stage trial, prompting the company to end research into the once-promising compound and take a $285 million charge. Development of an anti-coagulant, otamixaban, also will be halted after the drug showed no benefit over existing therapies in a study, the French drugmaker said in a statement today. Chief Executive Officer Chris Viehbacher reorganized Sanofi’s oncology business into a full-fledged division soon after taking over in December 2008, touting iniparib as a key program for the company’s transformation. Sanofi got the compound, also known as BSI-201, through the 2009 purchase of BiPar Sciences Inc. The French company agreed to pay as much as $500 million if iniparib met development goals.
Help employers find you! Check out all the jobs and post your resume.
Sanofi (SAN)’s experimental cancer treatment iniparib failed to help lung-cancer patients in a late-stage trial, prompting the company to end research into the once-promising compound and take a $285 million charge. Development of an anti-coagulant, otamixaban, also will be halted after the drug showed no benefit over existing therapies in a study, the French drugmaker said in a statement today. Chief Executive Officer Chris Viehbacher reorganized Sanofi’s oncology business into a full-fledged division soon after taking over in December 2008, touting iniparib as a key program for the company’s transformation. Sanofi got the compound, also known as BSI-201, through the 2009 purchase of BiPar Sciences Inc. The French company agreed to pay as much as $500 million if iniparib met development goals.
Help employers find you! Check out all the jobs and post your resume.